**SUPPLEMENTAL TABLE 1.** Oral antipsychotics taken by patients not included in the post hoc analysis\*

|  |  |  |
| --- | --- | --- |
| Preswitch Medication | Number of patients  (N = 52) | Reason for exclusion |
| Unknown | 28 | Case Report Form missing or incomplete information |
| Amisulpride/sulpride | 10 | N too low for grouping, deemed not appropriate to include in conventional antipsychotic group |
| Conventional antipsychotic  *(Low potency)* | 7 | N too low for grouping |
| Asenapine | 3 |
| Ziprasidone | 3 |
| Lurasidone | 1 |

**\***A minimum number of 19 patients was necessary to qualify as a preswitch oral group

**SUPPLEMENTAL TABLE 2.** Baseline dosesof preswitch oral antipsychotics

|  |  |  |  |
| --- | --- | --- | --- |
|  | Number of patients  (N =190) | Daily dose, mg | |
| **Median** | **Mean** |
| Aripiprazole | 56 | 15 | 17.7 |
| Risperidone\* | 52 | 3 | 3.12 |
| Conventional antipsychotic† *(High/medium potency)* | 36 |  |  |
| Haloperidol | 17 | 7.5 | 8.7 |
| Flupentixol | 2 | – | 7.5 |
| Fluphenazine | 1 | – | 20 |
| Perphenazine | 4 | – | 7.5 |
| Trifluoperazine‡ | 9 | – | 9.8 |
| Zuclopenthixol | 4 | – | 19.8 |
| Quetiapine | 26 | 300 | 317 |
| Olanzapine | 19 | 10 | 12.7 |

\*Includes 8 patients on oral paliperidone with dose conversion being 50% of oral risperidone (e.g. 12 mg/day of oral paliperidone is converted to 6 mg of oral risperidone equivalent); †Includes medium- and high-potency conventional antipsychotic; **‡**One subject in the trifluoperazine group received a 0.015mg dose, which was not included in the calculation of the mean dose

SD, standard deviation

**SUPPLEMENTAL TABLE 3.** Adverse events reported in ≥2 patients by preswitch antipsychotic group**.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **AL initiation phase (4 weeks)** | | | | | | **AL stabilization phase (8 weeks)** | | | | | | |
| **Patients, n** | **ARI n = 56** | **RIS\*  n = 52** | **CON n = 37** | **QUE n = 26** | **OLA  n = 19** | **Total n = 190** | **ARI  n = 49** | **RIS\* n = 47** | **CON n = 36** | **QUE  n = 22** | **OLA  n = 15** | **Total n = 169** |
| **Injection site pain** | 4 | 2 | 3 | 1 | 1 | 11 | 5 | 0 | 2 | 0 | 1 | 8 |
| **Insomnia** | 4 | 4 | 1 | 1 | 1 | 11 | 1 | 4 | 1 | 0 | 0 | 6 |
| **Akathisia** | 2 | 2 | 0 | 1 | 1 | 6 | 1 | 0 | 0 | 1 | 0 | 2 |
| **Dizziness** | 0 | 1 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Nausea** | 0 | 1 | 0 | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Decreased appetite** | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Headache** | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Schizophrenia** | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 3 |
| **Sedation** | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Toothache** | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Tremor** | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 2 |
| **Urinary tract infection** | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Blood pressure increased** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| **Cough** | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| **Hypertension** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |

If a patient experienced more than 1 AE in a period, the patient was counted only once in that period. \*Oral paliperidone was grouped with oral risperidone. AE, adverse event; AL, aripiprazole lauroxil; ARI, aripiprazole; CON, conventional; OLA, olanzapine; QUE, quetiapine; RIS, risperidone/paliperidone